drugset / Trial / NCT02211625

A Safety, Tolerability, PD and PK Study in Healthy Adults

NCT02211625

Phase 1 Completed 75 enrolled Trevena Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of TRV734 given as a single dose (Part A) and as multiple ascending doses (Part B) in healthy subjects.

Timeline

Start
2014-07
Primary completion
2014-10
Completion
2014-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Oxycodone Other / unclassified 10 mg
Subject TRV734 Unknown 125 mg

Indications

No indication recorded.